AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
These educational videos include presentations from keynote speakers Dr. John de Groot and Dr. Javier Villanueva-Meyer from University of California, San Francisco (UCSF), who shared updates and challenges in diagnosis and management of Glioblastoma (GBM), and the role for advanced PET imaging and imaging agents. Other educational videos include GBM patient Torey Gilbertson’s top tips for wearing the Optune Gio Device to treat GBM/rGBM, Dr. Caroline T. Goldin’s information about Tumor Treating Fields (TTFields), and Dr. Annick Desjardins’ presentation on Novel Immunotherapy Delivery Techniques in Glioblastoma Patients.
This annual event allows members of the brain cancer community to “DIRECTLY CONNECT” with top specialists, doctors, and researchers in the field to increase awareness of FDA approved treatment options, clinical trials, devices, diagnostics, etc., therefore, increasing patient access. Thank you to presenting sponsors Telix Pharmaceuticals and Novocure for making this free patient disease educational event and distribution the educational videos possible.
About Telix Pharmaceuticals
Telix is a biopharmaceutical company focused on the development and commercialization of
therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Visit http://www.telixpharma.com/ for further information.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer. Visit https://www.novocure.com/ for further information.
About the End Brain Cancer Initiative
To become a Corporate Sponsor of this event or support/donate to the End Brain Cancer Initiative’s increased access and health delivery for patients, mission, services and programs, please visit EndBrainCancer.org or contact Dellann Elliott Mydland, President & CEO, directly.
The End Brain Cancer Initiative (EBCI) is a 501(c)3 non-profit patient advocacy organization focused on disease education, awareness, outreach, increasing patient access and improving Standard of Care. EBCI, formerly known as the Chris Elliott Fund (CEF), is dedicated to ensuring that all patients diagnosed with brain cancer, brain tumors, or metastatic disease to the brain have equal access to advanced diagnostics, devices, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides the patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with their medical teams. Learn more about the End Brain Cancer Initiative at EndBrainCancer.org.
Dellann Elliott Mydland
End Brain Cancer Initiative
+1 4257858489
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
